A Phase 3 interventional study of terbinafine and Placebo in Onychomycosis, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 3 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-05-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.
Among the 20 studies testing terbinafine in Onychomycosis, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2006, is one of 10 in phase 3, and was the 2nd registered.
158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.
Browse Onychomycosis studies →1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:
Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →
Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 518 is above the median of 60 across 143 interventional studies indexed under Onychomycosis.
Median enrollment 100 across the 19 interventional studies. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Onychomycosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing terbinafine in Onychomycosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
Drug: terbinafine
vehicle (placebo) applied once daily for 48 weeks
Drug: Placebo
Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
Drug: terbinafine
vehicle (placebo) applied once daily for 24 weeks
Drug: Placebo
Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
Also known as: Lamisil
vehicle (placebo) applied once daily for 48 weeks
Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
Also known as: Lamisil
vehicle (placebo) applied once daily for 24 weeks
Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.
Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes. and no residual involvement of the target toenail. The complete cure was a composite binary variable defined as "Yes" if: * Mycological cure (negative KOH and negative culture for dermatophytes) and * No residual involvement of the target toenail "No" if otherwise
Time frame: 52 weeks
Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.
Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes. Mycological cure was a composite binary variable defined as "Yes"if : * Negative microscopy and * Negative culture for dermatophytes "No" if otherwise.
Time frame: 52 weeks
Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if * Mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise
Time frame: 52 weeks
Number of Participants Assessed With Adverse Events and Serious Adverse Events
An adverse event (AE) is any adverse change in health or side effect that occurs while the participant is receiving the treatment or within a previously specified period of time after the treatment has been completed. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening requires, inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.
Time frame: 52 weeks
| Milestone | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w |
|---|---|---|---|---|
| Started | 126 | 128 | 136 | 128 |
| Completed | 102 | 103 | 107 | 110 |
| Not completed | 24 | 25 | 29 | 18 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 2 | 3 | 3 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 10 | 10 | 6 |
| Withdrew: Lost to follow-up | 10 | 10 | 14 | 10 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes. and no residual involvement of the target toenail. The complete cure was a composite binary variable defined as "Yes" if: * Mycological cure (negative KOH and negative culture for dermatophytes) and * No residual involvement of the target toenail "No" if otherwise
| Percentage of Participants | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w |
|---|---|---|---|---|
| Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. | 0.79 (-2.16 to 2.19) | 0.78 (-2.16 to -2.16) | 1.47 (-0.55 to 3.49) | 0.00 (-0.55 to 3.49) |
Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes. Mycological cure was a composite binary variable defined as "Yes"if : * Negative microscopy and * Negative culture for dermatophytes "No" if otherwise.
| Percentage of Participants | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w |
|---|---|---|---|---|
| Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks. | 10.32 (-2.70 to 10.83) | 6.25 (-2.70 to 10.83) | 15.44 (5.54 to 19.10) | 3.13 (5.54 to 19.10) |
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if * Mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise
| Percentage of Participants | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w |
|---|---|---|---|---|
| Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks. | 1.59 | 2.34 | 3.68 | 1.56 |
An adverse event (AE) is any adverse change in health or side effect that occurs while the participant is receiving the treatment or within a previously specified period of time after the treatment has been completed. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening requires, inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.
| Participants | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w |
|---|---|---|---|---|
| Number of Participants Assessed With Adverse Events and Serious Adverse Events | 126 | 124 | 135 | 128 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Terbinafine 24 w | — | 2/126 (1.6%) | 35/126 (27.8%) |
| Vehicle 24 w | — | 7/124 (5.6%) | 38/124 (30.6%) |
| Terbinafine 48 w | — | 7/135 (5.2%) | 47/135 (34.8%) |
| Vehicle 48 w | — | 4/128 (3.1%) | 56/128 (43.8%) |
| Event | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/126 | 0/124 | 2/135 | 0/128 |
| Accidental deathGeneral disorders | 0/126 | 1/124 | 0/135 | 0/128 |
| PneumoniaInfections and infestations | 0/126 | 1/124 | 0/135 | 0/128 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/126 | 1/124 | 0/135 | 0/128 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/126 | 1/124 | 0/135 | 0/128 |
| Metastatic malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/126 | 1/124 | 0/135 | 0/128 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/126 | 1/124 | 1/135 | 0/128 |
| SyncopeNervous system disorders | 0/126 | 1/124 | 0/135 | 0/128 |
| Syncope vasovagalNervous system disorders | 0/126 | 1/124 | 0/135 | 0/128 |
| ConvulsionNervous system disorders | 1/126 | 0/124 | 0/135 | 0/128 |
| Event | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w |
|---|---|---|---|---|
| HeadacheNervous system disorders | 23/126 | 24/124 | 23/135 | 29/128 |
| NasopharyngitisInfections and infestations | 7/126 | 9/124 | 18/135 | 18/128 |
| Back painMusculoskeletal and connective tissue disorders | 7/126 | 7/124 | 9/135 | 10/128 |
| Influenza like illnessGeneral disorders | 2/126 | 1/124 | 0/135 | 8/128 |
| Upper respiratory tract infectionInfections and infestations | 4/126 | 6/124 | 8/135 | 8/128 |
| Age, Categorical(Participants) | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 107 | 101 | 116 | 100 | 424 |
| >=65 years | 19 | 27 | 20 | 28 | 94 |
| Sex: Female, Male(Participants) | Terbinafine 24 w | Vehicle 24 w | Terbinafine 48 w | Vehicle 48 w | Total |
|---|---|---|---|---|---|
| Female | 25 | 29 | 26 | 27 | 107 |
| Male | 101 | 99 | 110 | 101 | 411 |
The record gives a start of Dec 2006 and a primary completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Terbinafine